Fig. 4: HIF-1α is transferred by COPD-EVs in recipient cells. | Cell Death & Disease

Fig. 4: HIF-1α is transferred by COPD-EVs in recipient cells.

From: Extracellular vesicles from subjects with COPD modulate cancer initiating cells phenotype through HIF-1α shuttling

Fig. 4

A Analysis of CD133 modulation in HBEC-KRASV12high treated with EVs in the presence of SDF-1 neutralizing antibody (n = 3). B Quantification (pg/µl) of HIF-1α carried by COPD or HS-EVs via ELISA (n = 10). C On the left, representative dot plots show the higher positivity for HIF-1α in HBEC-KRASV12high treated with COPD-EVs compared to HS-EVs. On the right, the bar chart shows the percentage of HIF-1α in PKH26-labeled EV-treated HBEC-KRASV12high using flow cytometry (n = 7). D mRNA expression level of HIF-1α, VEGF and CAIX in EV-treated cells (n = 4). E Flow cytometry analysis of CD133+ and CD133+CXCR4+ cells after concomitant HIF-1α inhibition and EVs administration in HBEC-KRASV12high (n = 5). F Quantification of colonies constituted by HBEC-KRASV12high cells treated with 15 µg of COPD- or HS-EVs and concomitant HIF-1α inhibition in 3D culture condition. Untreated cells (NT) were used as a negative control. G Evaluation of migratory capabilities of HBEC-KRASV12high towards EGF and SDF-1 gradients after the treatment with HS- and COPD-EVs in the presence or not of HIF-1α inhibitor (n = 3). Data are expressed as mean and SEM.

Back to article page